Cholangiocarcinoma Clinical Trial
Official title:
Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma.
Successful palliation of biliary obstruction is the main goal for reducing morbidity and
mortality in patients with biliary disease and biliary obstruction related to
cholangiocarcinoma. Surgical intervention for the sale is unfortunately complicated by a
30-day postoperative mortality rate of between 7 and 24%. Moreover, because of recovery time
the quality of life following surgery is only improved in a minority. At present endoscopic
insertion of a plastic or metal stent is the method of choice to relieve obstructive
jaundice without the high morbidity and mortality associated with surgery. But this relief
is unfortunately temporary since stents tend to become obstructed and the fact that
effective biliary drainage in the proximal lesion is challenging.
Photodynamic Therapy (PDT) is a new therapeutic approach that specifically targets
neoplastic cells. This therapy involves the intravenous administration of a photosensitizing
agent followed by activation of the agent by illumination with non-thermal light of a
specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis.
A randomized controlled trial study by Ortner et all confirmed the significant advantage of
PDT with regard to relief of jaundice, quality of life, and survival.
In photodynamic therapy (PDT) the uniform distribution of externally applied light is
desirable but often difficult to achieve. An optical fiber tip producing cylindrical or
lateral light emission can facilitate the application of laser energy by direct implantation
of the tip into solid tumors. However, currently used FDA approved glass diffusers used in
standard of care PDT might break in the bile ducts causing injury since they are not meant
to be used within bile ducts through an endoscope or choledochoscope. Hence, there is a need
to evaluate and introduce more efficient and safe non-glass cylindrical optic fiber diffuser
for photo dynamic therapy in the bile ducts. Recent studies have shown that the Pioneer
plastic optic diffuser is safe and effective in photodynamic therapy, it can be also used
via a choledochoscope. We aim to add to the clinical evidence by conducting an open label
observational study trial using this fiber optic diffuser during photo dynamic therapy in
the bile ducts.
Cholangiocarcinoma (CCA) is the second most common malignancy arising within the liver, and
the association of this malignant condition with high morbidity and mortality is well
recognized. It originates from the epithelium of bile ducts or ductules. Two types have been
described: the peripheral type occurring in the parenchyma of the liver and the central type
occurring within or related to the major bile ducts. Surgery can offer a curative chance,
but only a minority of patients are candidates for this therapy at initial presentation
since most patients are found with an unresectable tumor.
In unresectable cases, the median survival is 6 months. Since morbidity and mortality from
CCA occurs because of biliary obstruction, successful palliation of that complication is the
main goal in these patients. Surgical biliary bypass can be offered in order to prolong life
and relieve symptoms. This intervention is unfortunately complicated by 30-day postoperative
mortality rate between 7 and 24%. Moreover, the quality of life following surgery is only
improved in a minority because of the time needed to recover from surgery.
Endoscopic biliary stenting during endoscopic retrograde cholangiopancreatography (ERCP)
offers relief from obstructive jaundice without the high morbidity and mortality associated
with surgery. In addition, a study by Luman et al even showed significant improvement in
emotional, cognitive and global health scores following stenting. But this relief is
unfortunately temporary since stents tend to become obstructed.
Local therapies including iridium brachytherapy and photodynamic therapy (PDT) may prevent
or postpone these problems.
For more information about PDT, please see the 'Citations' section.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT05678218 -
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
|
||
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05179486 -
Molecular Epidemiology of Biliary Tree Cancers
|
||
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Terminated |
NCT04304781 -
Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer
|
Phase 1 | |
Completed |
NCT03150615 -
Enteral Nutrition After Pancreaticoduodenectomy
|
N/A | |
Completed |
NCT01912053 -
Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT01439698 -
Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry
|
N/A | |
Terminated |
NCT01434459 -
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
|
Phase 1 | |
Completed |
NCT01206049 -
Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
|
Phase 2 | |
Recruiting |
NCT00973713 -
Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol
|
Phase 2 | |
Terminated |
NCT00975039 -
Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma
|
Phase 2 | |
Completed |
NCT00779454 -
Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma
|
Phase 2 | |
Terminated |
NCT04066491 -
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
|
Phase 2/Phase 3 | |
Recruiting |
NCT04340986 -
Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma
|
||
Active, not recruiting |
NCT04526106 -
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03603834 -
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 |